Drag a card by its title · ⚙ to size, swap or remove

The company

Allogene Therapeutics, Inc.

ALLO · Nasdaq

Health CareBiotechnologyNot moving yet

ALLO stood above a rising 150-day average in 29 of the last 52 weekly readings, and has been out of that trend for the last 9 weeks. It is 33.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 9
Industry in uptrend: 18% -12 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $1.2M
Officials’ trades on record: 0
Institutions holding: 197 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 29 of 52 weeks.

22 Apr – 21 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months14

Buyers · sellers0 · 6

Who	Did	Shares	Traded
Earl Martin DouglasSVP, General Counsel	sold	29,697at $2.12	21 Aug 2026filed 25 Aug 2026
Annie YoshiyamaSVP, Finance	sold	9,586at $2.31	21 Apr 2026filed 23 Apr 2026
Benjamin Machinas BeneskiSVP, Chief Technical Officer	sold	2,867at $2.50	31 Mar 2026filed 2 Apr 2026
David D. ChangPresident and CEO	sold	47,763at $2.47	16 Mar 2026filed 18 Mar 2026
Benjamin Machinas BeneskiSVP, Chief Technical Officer	sold	4,835at $2.47	16 Mar 2026filed 18 Mar 2026
Benjamin Machinas BeneskiSVP, Chief Technical Officer	sold	7,132at $2.60	2 Mar 2026filed 4 Mar 2026
Earl Martin DouglasSVP, General Counsel	sold	22,900at $1.76	2 Feb 2026filed 4 Feb 2026
Zachary RobertsEVP of R&D	sold	35,700at $1.77	2 Feb 2026filed 4 Feb 2026
Annie YoshiyamaSVP, Finance	sold	4,167at $1.72	2 Feb 2026filed 4 Feb 2026
Geoffrey M. ParkerCHIEF FINANCIAL OFFICER	sold	24,001at $1.76	2 Feb 2026filed 4 Feb 2026
David D. ChangPresident and CEO	sold	95,269at $1.80	2 Feb 2026filed 4 Feb 2026
Benjamin Machinas BeneskiSVP, Chief Technical Officer	sold	7,549at $1.73	2 Feb 2026filed 4 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders197+4 on the quarter

New · exited33 · 31

Reported value$637.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
BlackRock, Inc.added · filed 7 Aug 2026	30,146,963$62.7M	+11,055,868+57.9%
Frazier Life Sciences Management, L.P.added · filed 14 Aug 2026	22,446,668$46.7M	+18,650,000+491.2%
Pfizer Incunchanged · filed 13 Aug 2026	22,032,040$46.9M	00.0%
STATE STREET CORPadded · filed 7 Aug 2026	19,025,826$39.6M	+10,365,520+119.7%
TPG GP A, LLCunchanged · filed 14 Aug 2026	18,716,306$38.9M	00.0%
Sio Capital Management, LLCnew · filed 14 Aug 2026	13,323,431$27.7M	+13,323,431
PRIMECAP MANAGEMENT COadded · filed 14 Aug 2026	13,123,440$27.3M	+4,743,600+56.6%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	12,166,636$25.3M	+5,245,286+75.8%
FMR LLCadded · filed 13 Aug 2026	12,009,043$25.0M	+10,419,213+655.4%
CITADEL ADVISORS LLCadded · filed 14 Aug 2026	10,087,770$21.0M	+3,294,150+48.5%